TipRanks
Advertisement
Advertisement
Aytu BioPharma reports Q3 EPS (53c), consensus (43c)
PremiumThe FlyAytu BioPharma reports Q3 EPS (53c), consensus (43c)
5M ago
AYTU Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
AYTU Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
Aytu BioScience Amends Warrants, Modifying Security Holder Rights
Premium
Company Announcements
Aytu BioScience Amends Warrants, Modifying Security Holder Rights
6M ago
Aytu BioPharma announces nationwide commercial launch of EXXUA
PremiumThe FlyAytu BioPharma announces nationwide commercial launch of EXXUA
9M ago
Aytu BioPharma announces commercial availability of EXXUA tablets
Premium
The Fly
Aytu BioPharma announces commercial availability of EXXUA tablets
10M ago
Aytu BioScience Stockholders Approve Key Proposals
Premium
Company Announcements
Aytu BioScience Stockholders Approve Key Proposals
10M ago
Aytu BioPharma announces patent term extension for EXXUA
PremiumThe FlyAytu BioPharma announces patent term extension for EXXUA
12M ago
Aytu BioPharma management to meet with Lake Street
Premium
The Fly
Aytu BioPharma management to meet with Lake Street
1y ago
Aytu BioPharma price target lowered to $7 from $9 at Maxim
Premium
The Fly
Aytu BioPharma price target lowered to $7 from $9 at Maxim
1y ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―